Table 1 Demographic and clinical characteristics of the patients
Variable | AAC patients receiving PC treatment (n = 44) |
|---|---|
Sex [male (%)] | 28 (63.6%) |
Age (years) | 76 (65–82) |
Length of stay (days) | 15 (8–27) |
Intensive care unit stay | 16 (36.4%) |
Grade II/III | 18 (40.9%)/26 (59.1%) |
Cardiovascular dysfunction | 8 (18.2%) |
Neurological dysfunction | 14 (31.8%) |
Respiratory dysfunction | 10 (22.7%) |
Renal dysfunction | 16 (36.4%) |
aCCI | 5 (4–6) |
Charlson comorbidity | |
Prior myocardial infarction | 5 (11.4%) |
Congestive heart failure | 4 (9.1%) |
Diabetes | 12 (27.3%) |
Cerebrovascular disease | 11 (25.0%) |
Nonmetastatic solid tumor | 7 (15.9%) |
Metastatic solid tumor | 7 (15.9%) |
Moderate or severe renal disease | 4 (9.1%) |
Ulcer disease | 3 (6.8%) |
Preoperative jaundice | 9 (20.5%) |
Common bile duct obstruction | 3 (6.8%) |
Body temperature (℃) | 38.1 (37.1–39.0) |
Preoperative fever (≥ 37.7℃) | 27 (61.4%) |
Initial laboratory values | |
Platelets (× 109 L) | 173.5 (117.5–322.0) |
WBC counts (× 109 L) | 10.3 (7. 5–16.0) |
Neutrophil granulocytes (%) | 83.2 (76.2–92.6) |
ALT (U/L) | 30.5 (19.3–62.0) |
STB (μmol/L) | 19.5 (13.0–30.7) |
CB (μmol/L) | 1.6 (0–10.5) |
UCB (μmol/L) | 6.6 (3.3–12.6) |
Antibacterial treatment before PC | |
Cephalosporin only | 14 (31.8%) |
Carbapenem only | 9 (20.5%) |
Fluoroquinolone only | 1 (2.3%) |
Multi-drug combination | 17 (38.6%) |